Phase I dose-escalation trial of clofarabine followed by escalating doses of fractionated cyclophosphamide in children with relapsed or refractory acute leukemia. Pediatr Blood Cancer. 2012;59:1252–8.Abd Elmoneim A, et al. Phase I dose-escalation trial of clofarabine followed by escalating doses ...
Abstract B118: A phase 1, open-label multiple dose escalation trial to determine safety and tolerability of once daily OPB-111077 in subjects with advanced cancer doi:10.1158/1535-7163.TARG-15-B118Background: OPB-111077 is a new chemical entity with anticancer activity in vitro and in human ...
The trial consists of two stages: the first stage is an open-label, single-dose, dose-escalation study to determine the optimal biological dose (OBD) of YOLT-201; the second stage is an open-label, single-dose, dose-expansion study to preliminarily assess the safety and preliminary efficacy...
BioEclipse Therapeutics™ announced the initiation of patient enrollment in a Phase 1 dose-escalation trial to treat refractory solid tumors. The trial marks the first-in-human study of CRX100, an intravenously-delivered cancer therapy designed to target and...
Dose escalation is expected to enroll approximately 18 patients to establish the initial RP2D. The safety population will include all patients in the study who received any dose of CA-4948, and the efficacy population will include patients who have a valid baseline and post-baseline disease ...
Summary of preliminary data from ongoing Phase 1 Trial of CDX-527: As of the data cut-off on April 16, 2021, 11 patients were enrolled in the first 5 dose escalation cohorts, 0.03 mg/kg through 3 mg/kg. CDX-527 was well tolerated, ...
While efficacy was not a primary readout for the dose escalation trial, VT1021 did demonstrate single-agent activity in multiple patients. Out of 38 patients who received at least one dose of VT1021 in the escalation phase, 28 patients were considered evaluable based on the criteria of completi...
(EDB+FN), a non-cellular structural component within the tumor extra-cellular matrix. PYX-201 is being evaluated in an open-label, multicenter, Phase 1 dose escalation trial in patients with relapsed or r...
we hypothesized zelenirstat would be safe to administer and show anticancer activity.Methods:Patients (pts) with advanced solid tumors and relapsed/refractory (R/R) B-cell lymphomas were enrolled in a multicenter, open label, phase I dose escalation trial of oral daily zelenirstat, administered ...
et al. Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial. Nat Med 28, 1022–1030 (2022). https://doi.org/10.1038/s41591-022-01762-x Download citation Received30 June 2021 Accepted28 February 2022 ...